Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise

"We are pleased with FDA's grant of pediatric exclusivity for the Nucynta Franchise," said Thomas Smith, M.D., Collegium's Chief Medical Officer. "This grant of pediatric exclusivity enhances the value of the Nucynta franchise and bolsters our near-term outlook. Collegium is proud to lead with science in support of people living with serious medical conditions and the communities we serve." Nucynta ER is currently approved in the U.S. for the management of severe and persistent pain in adults that requires ...